Serum endostatin levels in patients with metastatic and non-metastatic well-differentiated thyroid cancer.
BACKGROUND
The growth of a tumour is limited by its neovascularisation. Angiogenesis is dependent on a dynamic balance between its activators and inhibitors. One of the most important antiangiogenic factors is endostatin. The aim of the study was to assess the usefulness of serum endostatin levels as a potential marker of metastases of well-differentiated thyroid cancer, and to estimate the effect of endogenous TSH stimulation on serum endostatin levels.


METHODS
The study group consisted of 68 patients with differentiated thyroid cancer. We provided a cross-sectional analysis of the study group divided into patients with distant and/or locoregional metastases and patients with remission, and compared it with serum endostatin levels of healthy volunteers. Serum endostatin concentration was measured by ELISA kits (R & D Systems).


RESULTS
Median endostatin concentration was significantly higher in patients with distant metastases than in patients with remission (141.95 v. 105.345 ng/ml, p < 0.05). This was not observed in patients with locoregional metastases. Serum endostatin levels were significantly higher in the study group, including patients with remission, than in the control group of healthy volunteers (remission v. healthy median 105.3 v. 88.1 ng/ml, p < 0.05). During endogenous TSH stimulation, endostatin levels significantly decreased (122.94 v. 93.60 ng/ml, p < 0.05).


CONCLUSIONS
The study indicates that endogenous TSH stimulation plays a role in the regulation of endostatin secretion. Although median serum endostatin levels are higher in patients with distant metastases than in patients with remission, its clinical usefulness is limited due to the overlapping data between the study groups. (Pol J Endocrinol 2010; 61 (1): 7-12).
Kłubo-Gwieździńska
Joanna
J
Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland. gwiezdzinska@gmail.com
Junik
Roman
R
Kopczyńska
Ewa
E
D018263:Adenocarcinoma, Follicular / Q000097:blood* / Q000473:pathology / Q000556:secondary*; D000231:Adenocarcinoma, Papillary / Q000097:blood* / Q000473:pathology / Q000556:secondary*; D000328:Adult; D003430:Cross-Sectional Studies; D043169:Endostatins / Q000097:blood*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood / Q000556:secondary; D008175:Lung Neoplasms / Q000097:blood / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012016:Reference Values; D013964:Thyroid Neoplasms / Q000097:blood* / Q000473:pathology*; D013972:Thyrotropin / Q000378:metabolism
D043169:Endostatins; D013972:Thyrotropin